Hypera SA (HM6A) AI Stock Analysis

Hypera SA

(Frankfurt:HM6A)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue and profit growthThe rebound in revenue and net income shows renewed commercial momentum across Hypera’s portfolio. Combined with gross and net margins of about 59% and 20%, respectively, this provides a durable earnings base that can support continued investment in brands, innovation, and distribution.

Negative Factors

Prolonged flu-category weaknessContinued weakness in flu medicines can weigh on near-term portfolio growth and make results more dependent on newer launches and other therapeutic categories. Although management expects eventual recovery, the pressure may persist across several reporting periods.

Hypera SA (HM6A) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.74B
Dividend Yield: 5.70%
Average Volume (3M): 1,214
Price to Earnings (P/E): 7.9
Beta (1Y): -0.08
Revenue Growth: 35.43%
EPS Growth: 122.07%
Country: Germany
Employees: 10,564
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Hypera SA Business Overview & Revenue Model

Company Description

Hypera S.A. is a prominent pharmaceutical enterprise primarily operating within Brazil. The company maintains a diverse product portfolio that includes a vast array of prescription medications, marketed under numerous brand names such as Adacne, Adde...

Hypera SA Earnings Call Summary

Earnings Call Date:Oct 26, 2026(Q3-2026)|% Change Since:4.05%|Next Earnings Date:Feb 18, 2027

Earnings Call SentimentPositive

The call was broadly positive. Hypera delivered solid revenue, EBITDA, net income, cash conversion, working-capital, and leverage improvements, while Semavy's launch materially exceeded initial expectations and expanded the company's chronic-care portfolio. The main challenges were weaker flu-related demand, higher launch and marketing expenses, short-term Semavy margin dilution, a slower institutional-market ramp, and uncertainty around near-term category and margin trends. Overall, the highlights significantly outweighed the lowlights.

Positive Updates

Sell-Out Growth Outpaced the Target Market

Sell-out grew 6.6%, exceeding the 5.4% growth of Hypera's target market, while the company reported market share gains in its operating categories.

Negative Updates

Slower Target-Market Growth and Flu-Medicine Decline

The target market grew at a slower pace than in the first half of the year, mainly because flu-medication sales declined 15%, driven by a 23% decrease in reported flu cases in the third quarter of 2026.

Company Guidance

Management expects October sell-out growth of low teens, with the base portfolio at mid-single digits and the remainder coming from Semavy; Semavy is expected to double the approximately 94,000 units sold in the previous month and continue leading until the end of 2027. The flu category will probably see a negative impact until the first quarter, with recovery expected in the third quarter of 2027, while El Niño should continue until the end of the first quarter or the beginning of the second quarter of 2027. Management has not changed its expectations for margins and does not expect any variations that will change the trends in the second and third quarters; investments will reduce starting in 2027, and the company expects cash generation for next year to be slightly higher than this year. The goal is to reach 1.5x net debt to EBITDA, with management believing it will be close to that level at the end of 2027, while institutional-market sales are targeted at BRL 1.5 billion by 2028, or maybe for the future, maybe for 2030.

Hypera SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:HM6A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDY	67Neutral	$11.87B	40.24	7.37%	0.59%	-10.52%	-55.45%
VTRS	63Neutral	$21.86B	-52.88	-2.79%	2.52%	4.92%	87.81%
HLN	62Neutral	$37.64B	17.61	9.89%	1.43%	4.99%	12.37%
AMRX	59Neutral	$7.49B	43.24	-326.75%	―	9.28%	4917.17%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	46Neutral	$2.19B	-1.26	-55.97%	7.35%	-4.18%	-2138.82%

* Healthcare Sector Average

Performance Comparison

DE:HM6A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:HM6A	Hypera S.A. Sponsored ADR	3.60	-0.43	-10.67%
RDY	Dr. Reddy's Laboratories Ltd	14.17	0.83	6.25%
VTRS	Viatris, Inc.	19.04	8.87	87.19%
PRGO	Perrigo Company	15.78	-2.98	-15.89%
AMRX	Amneal Pharma	21.51	10.32	92.14%
HLN	Haleon PLC Sponsored ADR	8.66	-0.54	-5.91%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Hypera SA AI Stock Analysis